Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Pediatr Blood Cancer. 2023 Feb 15;70(5):e30251. doi: 10.1002/pbc.30251

Figure 3. AMkL vs other AML Kaplan–Meier curves per trial.

Figure 3.

(A) Event-free survival and (B) overall survival of all cases of AMkL (FAB M7) versus all other centrally-reviewed AML FAB subtypes from trial AAML0531. As shown, M7 cases have relatively equivalent EFS and OS compared to other FAB subgroups. (C) EFS and (D) OS of all cases of AMkL versus all other centrally reviewed AML FAB subtypes from trial AAML1031; as shown AMkL have decreased 5-year OS compared to the other FAB subgroups. In general, AMkL on AAML0531 had better outcomes than AMkL on AAML1031.